Natixis Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.11M | Buy |
19,495
+5,878
| +43% | +$322K | ﹤0.01% | 1444 |
|
|
2026
Q1 | $769K | Buy |
+13,617
| New | +$794K | ﹤0.01% | 1435 |
|
|
2025
Q4 | – | Sell |
-11,018
| Closed | -$597K | – | 1611 |
|
|
2025
Q3 | $597K | Sell |
11,018
-14,212
| -56% | -$813K | ﹤0.01% | 1443 |
|
|
2025
Q2 | $1.39M | Sell |
25,230
-7,996
| -24% | -$471K | ﹤0.01% | 1199 |
|
|
2025
Q1 | $2.35M | Buy |
33,226
+13,488
| +68% | +$907K | ﹤0.01% | 1029 |
|
|
2024
Q4 | $1.3M | Buy |
+19,738
| New | +$1.32M | ﹤0.01% | 1226 |
|
|
2024
Q3 | – | Sell |
-18,901
| Closed | -$1.56M | – | 1577 |
|
|
2024
Q2 | $1.56M | Sell |
18,901
-36,548
| -66% | -$3.04M | ﹤0.01% | 1126 |
|
|
2024
Q1 | $4.84M | Sell |
55,449
-4,170
| -7% | -$373K | 0.01% | 799 |
|
|
2023
Q4 | $5.75M | Sell |
59,619
-248
| -0.4% | -$21.9K | 0.02% | 714 |
|
|
2023
Q3 | $5.3M | Buy |
59,867
+116
| +0.2% | +$10.3K | 0.02% | 695 |
|
|
2023
Q2 | $5.18M | Sell |
59,751
-1,207
| -2% | -$114K | 0.02% | 688 |
|
|
2023
Q1 | $5.93M | Sell |
60,958
-1,387
| -2% | -$144K | 0.02% | 641 |
|
|
2022
Q4 | $6.45M | Sell |
62,345
-13,239
| -18% | -$1.24M | 0.02% | 612 |
|
|
2022
Q3 | $6.41M | Buy |
75,584
+7,171
| +10% | +$639K | 0.03% | 561 |
|
|
2022
Q2 | $5.67M | Buy |
68,413
+8,047
| +13% | +$641K | 0.02% | 612 |
|
|
2022
Q1 | $4.65M | Sell |
60,366
-4,016
| -6% | -$336K | 0.02% | 703 |
|
|
2021
Q4 | $5.69M | Buy |
64,382
+8,867
| +16% | +$732K | 0.02% | 625 |
|
|
2021
Q3 | $4.29M | Buy |
55,515
+25,314
| +84% | +$2M | 0.02% | 689 |
|
|
2021
Q2 | $2.52M | Buy |
30,201
+10,137
| +51% | +$804K | 0.01% | 836 |
|
|
2021
Q1 | $1.51M | Sell |
20,064
-34,582
| -63% | -$2.82M | 0.01% | 955 |
|
|
2020
Q4 | $4.79M | Buy |
54,646
+16,968
| +45% | +$1.35M | 0.03% | 577 |
|
|
2020
Q3 | $2.87M | Buy |
37,678
+4,153
| +12% | +$420K | 0.02% | 696 |
|
|
2020
Q2 | $4.13M | Buy |
33,525
+18,053
| +117% | +$1.79M | 0.03% | 570 |
|
|
2020
Q1 | $1.31M | Buy |
15,472
+1,814
| +13% | +$156K | 0.01% | 836 |
|
|
2019
Q4 | $1.16M | Buy |
+13,658
| New | +$1.03M | 0.01% | 952 |
|
|
2019
Q3 | – | Sell |
-29,499
| Closed | -$2.53M | – | 1106 |
|
|
2019
Q2 | $2.53M | Sell |
29,499
-3,943
| -12% | -$337K | 0.02% | 705 |
|
|
2019
Q1 | $2.97M | Buy |
33,442
+434
| +1% | +$40.2K | 0.03% | 619 |
|
|
2018
Q4 | $2.81M | Sell |
33,008
-743
| -2% | -$70.7K | 0.03% | 587 |
|
|
2018
Q3 | $3.27M | Sell |
33,751
-1,105
| -3% | -$110K | 0.03% | 621 |
|
|
2018
Q2 | $3.28M | Buy |
34,856
+17,437
| +100% | +$1.53M | 0.03% | 603 |
|
|
2018
Q1 | $1.41M | Sell |
17,419
-430
| -2% | -$36.9K | 0.01% | 842 |
|
|
2017
Q4 | $1.59M | Buy |
17,849
+12
| +0.1% | +$1.04K | 0.02% | 769 |
|
|
2017
Q3 | $1.66M | Buy |
17,837
+2,592
| +17% | +$229K | 0.02% | 763 |
|
|
2017
Q2 | $1.39M | Buy |
15,245
+55
| +0.4% | +$5K | 0.02% | 794 |
|
|
2017
Q1 | $1.33M | Buy |
15,190
+2,478
| +19% | +$220K | 0.01% | 798 |
|
|
2016
Q4 | $1.05M | Buy |
12,712
+1,826
| +17% | +$157K | 0.01% | 817 |
|
|
2016
Q3 | $1.01M | Buy |
+10,886
| New | +$1.03M | 0.01% | 805 |
|
|
2014
Q3 | – | Sell |
-3,508
| Closed | -$218K | – | 1032 |
|
|
2014
Q2 | $218K | Sell |
3,508
-495
| -12% | -$29.9K | ﹤0.01% | 1263 |
|
|
2014
Q1 | $273K | Sell |
4,003
-5,422
| -58% | -$400K | ﹤0.01% | 1107 |
|
|
2013
Q4 | $663K | Buy |
9,425
+3,463
| +58% | +$235K | 0.01% | 840 |
|
|
2013
Q3 | $430K | Buy |
+5,962
| New | +$396K | 0.01% | 886 |
|
Other funds holding BMRN
VPC
Natixis Advisors's BMRN Position: Q2 2026 in Review
Natixis Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 43% in Q2 2026, buying an estimated $322K and bringing the position to 19,495 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1444.
Natixis Advisors first reported a position in BMRN in Q3 2013 and has held it in 41 quarters since. The position peaked at $6.45M in Q4 2022. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Natixis Advisors held 19,495 shares of BioMarin Pharmaceuticals worth $1.11M as of Q2 2026.
- Natixis Advisors bought 5,878 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $322K.
- BioMarin Pharmaceuticals made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1444 holding.
- Natixis Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2013 and has held it in 41 quarters since.
- Natixis Advisors's BioMarin Pharmaceuticals position peaked at $6.45M in Q4 2022.
- 562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.